IP Library Granted Patent US 10,550,434
Granted Patent B2
US 10,550,434 · App. 15/821,960 · Granted Feb 4, 2020

Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof

Inventors: Olga Iakoubova (Pleasanton, CA); James J. Devlin (Lafayette, CA)
Assignee: Celera Corporation
C12Q1/6883C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,550,434
App. No.
15/821,960
Granted
Feb 4, 2020
Kind
B2
Abstract

The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Claims (20)

1. A method for identifying a human as having an increased risk for myocardial infarction, the method comprising:

a) testing nucleic acid from said human for a polymorphism in gene WDR12 as represented by position 101 of SEQ ID NO:25288 or its complement by contacting said nucleic acid with an allele-specific primer that specifically hybridizes to G at said position 101 of SEQ ID NO:25288 or C at said complement;

b) detecting said G or said C;

c) identifying said human as having an increased risk for myocardial infarction due to the presence of said G or said C; and

d) administering a therapeutic agent suitable for prevention or treatment of myocardial infarction to said human.

2. The method of claim 1 , wherein said allele-specific primer comprises SEQ ID NO:73593 or a sequence fully complementary thereto.

3. The method of claim 1 , wherein said detecting comprises detecting the presence of an amplicon.

4. The method of claim 1 , wherein said allele-specific primer is detectably labeled with a fluorescent dye.

5. The method of claim 1 , wherein said human is homozygous for said G or said C.

6. The method of claim 1 , wherein said human is heterozygous for said G or said C.

7. A method for identifying a human as having an increased risk for myocardial infarction, the method comprising:

a) testing nucleic acid from said human for a polymorphism in gene WDR12 as represented by position 101 of SEQ ID NO:25288 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO:25288 or C at said complement;

b) detecting said G or said C;

c) identifying said human as having an increased risk for myocardial infarction due to the presence of said G or said C; and

d) administering a therapeutic agent suitable for prevention or treatment of myocardial infarction to said human.

8. The method of claim 7 , wherein said method comprises nucleic acid amplification by polymerase chain reaction (PCR).

9. The method of claim 7 , wherein said oligonucleotide is an allele-specific probe.

10. The method of claim 7 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.

11. The method of claim 7 , wherein said human is homozygous for said G or said C.

12. The method of claim 7 , wherein said human is heterozygous for said G or said C.

Continuity (9)
Continuation 15058462 · Mar 2, 2016
Continuation 14158976 · Jan 20, 2014
Division 12337905 · Dec 18, 2008
Division 10741600 · Dec 22, 2003
Provisional Application 60434778 · Dec 20, 2002
Provisional Application 60453135 · Mar 10, 2003
Provisional Application 60466412 · Apr 30, 2003
Provisional Application 60504955 · Sep 3, 2003
Related Publication 20180251842A1 · Sep 6, 2018